Hank Lai - Foresee Pharmaceuticals Independent Director
| 6576 Stock | TWD 73.70 0.10 0.14% |
Insider
Hank Lai is Independent Director of Foresee Pharmaceuticals Co since 2018.
| Tenure | 6 years |
| Phone | 886 2 7750 0188 |
| Web | https://www.foreseepharma.com |
Foresee Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1768) % which means that it has lost $0.1768 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3539) %, meaning that it generated substantial loss on money invested by shareholders. Foresee Pharmaceuticals' management efficiency ratios could be used to measure how well Foresee Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MaoChing Chen | Chong Hong Construction | N/A | |
| JinnDer Jin | GeneFerm Biotechnology Co | N/A | |
| Yaomin Lee | Chong Hong Construction | N/A | |
| Fangcai Qiu | GeneFerm Biotechnology Co | N/A | |
| Banson Lin | Synmosa Biopharma | N/A | |
| YuonChan Liu | Giant Manufacturing Co | N/A | |
| Nuzhu Qiu | GeneFerm Biotechnology Co | N/A | |
| ChenTung Chen | Great Taipei Gas | N/A | |
| JungShan Wang | Chong Hong Construction | N/A | |
| PoFong Lin | Great Taipei Gas | N/A | |
| ChinTzu Lin | Ruentex Development Co | N/A | |
| ChiaoLi Pan | Giant Manufacturing Co | N/A | |
| Yiren Ji | GeneFerm Biotechnology Co | N/A | |
| Qimian Su | GeneFerm Biotechnology Co | N/A | |
| ChiHao Wu | Great Taipei Gas | N/A | |
| KuoHsing Huang | Chong Hong Construction | N/A | |
| JiaXin Zhang | Synmosa Biopharma | N/A | |
| PiYu Wang | Giant Manufacturing Co | N/A | |
| Jin Zheng | Giant Manufacturing Co | N/A | |
| ChingChi Chen | Kinko Optical Co | N/A | |
| Zongmin Chen | GeneFerm Biotechnology Co | N/A | |
Management Performance
| Return On Equity | -0.35 | |||
| Return On Asset | -0.18 |
Foresee Pharmaceuticals Leadership Team
Elected by the shareholders, the Foresee Pharmaceuticals' board of directors comprises two types of representatives: Foresee Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foresee. The board's role is to monitor Foresee Pharmaceuticals' management team and ensure that shareholders' interests are well served. Foresee Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foresee Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sheila Chuang, Accounting Mang | ||
| Mathieu Boudreau, Deputy General Manager-Business Development | ||
| MengKung Chan, Chief Officer | ||
| John Mao, Senior Deputy General Manager | ||
| Liangshang Gan, General Manager | ||
| David Lau, Senior Deputy General Manager-NCE Preclinical and Clinical Development | ||
| Vincent Yen, Director | ||
| Sonia Wu, Director | ||
| JiaLong Lee, Director | ||
| Kunhong Lai, Independent Director | ||
| Max Chan, Chief Financial Officer, Head of Finance | ||
| Yuhua Li, Deputy General Manager-RD Pipeline | ||
| FuShiow Yin, Independent Director | ||
| Hank Lai, Independent Director | ||
| Wenjin Yang, Chief Scientific Officer, Deputy General Manager | ||
| Jagdish Parasrampuria, Senior Deputy General Manager-Drug Product | ||
| WenChi Lee, Independent Director | ||
| Peifen Chou, Consultant | ||
| Ronald Dadino, Senior Deputy General Manager-Pharmaceutical Manufacturing | ||
| Yisheng Lee, Chief Medical Officer, Director | ||
| Jeff Wang, Director | ||
| Digger Chen, General Counsel, Deputy General Manager | ||
| Benjamin Chien, Chairman of the Board, Acting General Manager, Chief Strategy Officer |
Foresee Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Foresee Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | |||
| Return On Asset | -0.18 | |||
| Profit Margin | (1.57) % | |||
| Operating Margin | (1.57) % | |||
| Current Valuation | 10.39 B | |||
| Shares Outstanding | 118.12 M | |||
| Shares Owned By Insiders | 35.40 % | |||
| Shares Owned By Institutions | 3.14 % | |||
| Price To Book | 10.24 X | |||
| Price To Sales | 39.29 X |
Pair Trading with Foresee Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Foresee Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Foresee Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Foresee Stock
Moving against Foresee Stock
| 0.62 | 2345 | Accton Technology Corp | PairCorr |
| 0.57 | 0050 | YuantaP shares Taiwan | PairCorr |
| 0.55 | 0057 | Fubon MSCI Taiwan | PairCorr |
| 0.46 | 0053 | YuantaP shares Taiwan | PairCorr |
| 0.43 | 1591 | Inmax Holding | PairCorr |
The ability to find closely correlated positions to Foresee Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Foresee Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Foresee Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Foresee Pharmaceuticals Co to buy it.
The correlation of Foresee Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Foresee Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Foresee Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Foresee Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Foresee Stock Analysis
When running Foresee Pharmaceuticals' price analysis, check to measure Foresee Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foresee Pharmaceuticals is operating at the current time. Most of Foresee Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Foresee Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foresee Pharmaceuticals' price. Additionally, you may evaluate how the addition of Foresee Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.